Axonics devices are implanted to help control incontinence and can last as long as 17 to 24 years or more Raymond Cohen says he knew the moment when Axonics Inc., which he co-founded in 2013, would ...
Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...
The deal would set up Boston Scientific to compete directly with Medtronic in the market for neuromodulation devices that ...
Based in Irvine, device maker Axonics Inc. reported fourth-quarter revenue climbed 61% to $85.6 million to $86 million, topping the $78.1 million expected by analysts. “This quarter’s record revenue ...
Jan 8 (Reuters) - Medical device maker Boston Scientific (BSX.N), opens new tab said on Monday it had agreed to buy Axonics Inc (AXNX.O), opens new tab for $3.7 billion, gaining access to devices used ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...
Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting-edge ...
Sacral neuromodulation may not work for everyone, but Axonics is hoping to more accurately identify those who may indeed be good candidates for the technology. The devicemaker has acquired a new ...
Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...
Boston Scientific Corporation (NYSE:BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $71 in cash per share, representing an enterprise value of approximately $3.4 billion and an equity value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback